Open Access

Soluble amyloid-β, effect on cerebral arteriolar regulation and vascular cells

  • Hans H Dietrich1Email author,
  • Chuanxi Xiang2,
  • Byung H Han2,
  • Gregory J Zipfel3 and
  • David M Holtzman4
Molecular Neurodegeneration20105:15

DOI: 10.1186/1750-1326-5-15

Received: 7 January 2010

Accepted: 13 April 2010

Published: 13 April 2010



Evidence indicates that soluble forms of amyloid-β (Aβ) are vasoactive, which may contribute to cerebrovascular dysfunction noted in patients with Alzheimer's Disease and cerebral amyloid angiopathy. The effects of soluble Aβ on penetrating cerebral arterioles - the vessels most responsible for controlling cerebrovascular resistance - have not been studied.


Freshly dissolved Aβ1-40 and Aβ1-42, but not the reverse peptide Aβ40-1 constricted isolated rat penetrating arterioles and diminished dilation to adenosine tri-phosphate (ATP). Aβ1-42 also enhanced ATP-induced vessel constriction. Aβ1-40 diminished arteriolar myogenic response, and an anti-Aβ antibody reduced Aβ1-40 induced arteriolar constriction. Prolonged Aβ exposure in vessels of Tg2576 mice resulted in a marked age-dependent effect on ATP-induced vascular responses. Vessels from 6 month old Tg2576 mice had reduced vascular responses whereas these were absent from 12 month old animals. Aβ1-40 and Aβ1-42 acutely increased production of reactive oxygen species (ROS) in cultured rat cerebro-microvascular cells. The radical scavenger MnTBAP attenuated this Aβ-induced oxidative stress and Aβ1-40-induced constriction in rat arterioles.


Our results suggest that soluble Aβ1-40 and Aβ1-42 directly affect the vasomotor regulation of isolated rodent penetrating arterioles, and that ROS partially mediate these effects. Once insoluble Aβ deposits are present, arteriolar reactivity is greatly diminished.


Amyloid beta (Aβ) peptides are naturally occurring cleavage products of the amyloid precursor protein and produced via β- and γ-secretase resulting in soluble Aβ monomers [1]. Important species include peptides containing 40 and 42 amino acid residues (Aβ1-40 and Aβ1-42) [2]. Monomers of Aβ can aggregate resulting in deposits of fibrillar Aβ both as neuritic plaques and, within blood vessels, as cerebral amyloid angiopathy (CAA). Such deposits are hallmarks of Alzheimer's Disease (AD) [1]. Several lines of evidence suggest that not only Aβ aggregates but soluble Aβ species may also contribute to AD with its vasoactive properties. Cerebral hypoperfusion prior to the onset of AD has been observed [3]. In animal models of AD, some but not all studies suggest that soluble Aβ may decrease myogenic response, cerebral blood flow (CBF) and vasodilator responses [410]. This implies that soluble Aβ may have an effect on vascular regulation possibly affecting neuronal function [5], potentially contributing to ischemic brain damage [4]. To elucidate the vascular effects of soluble Aβ on the cerebral circulation, studies infusing soluble Aβ into rat [11] or superfusing mouse cortex [12] found that soluble Aβ acutely decreased CBF and response to vasodilators, it also increased vascular resistance and constrictor response. In ex vivo studies, soluble Aβ causes cerebral artery constriction, reduced dilation and/or increased constriction to endothelium-dependent dilators and vasoconstrictors, respectively [7, 1216]. The mechanism(s) by which soluble Aβ interferes with vascular function is not fully understood. But increased production of reactive oxygen species (ROS) has been described [15, 1719]. However, other mechanisms such as increased intracellular calcium activity [16] or decreased endothelial nitric oxide availability [20] have been reported. Because endothelium-dependent dilation rather than smooth muscle function [4, 15] was impaired, studies concluded that soluble Aβ causes endothelial dysfunction resulting in the observed reduced vasomotor function [4, 15, 16].

To date, studies examining the functional effects of soluble Aβ on the cerebro-vasculature have been limited to cortical CBF measurements following topical application of soluble Aβ [12] and measurements of isolated cerebral arteries exposed to soluble Aβ [12, 20]. No data regarding intracerebral micro-vessels exist. These vessels are exposed to both soluble Aβ as sites of Aβ clearance [21] and substantial CAA which forms in the vessel wall. Penetrating arterioles contribute significantly to the local regulation of CBF by controlling as much as 25% of total arterial resistance, exercising strong myogenic response [22] and differ in physiological response from proximal pial vessels and arteries [23]. For these reasons, it is important to examine the effects of Aβ on these critical microvessels and determine which mechanisms are involved. Finally, the effect of prolonged exposure to endogenous Aβ on cerebral arterioles has not been previously described.

Here we show strong effects of both soluble Aβ1-40 and Aβ1-42 on both vasoconstriction and vasodilation in penetrating arterioles, these effects are mediated in part by ROS. Further, prolonged exposure to high levels of Aβ in a mouse model with CAA was accentuated with very poor arteriolar function.


Isolation and cannulation of penetrating arterioles

All procedures were approved by the Washington University Advisory Committee for Animal Resources. Male Sprague-Dawley rats (350-450 g, Harlan, Indianapolis, IN) were anesthetized with pentobarbital sodium (65 mg/kg intraperitoneally) and sacrificed. Transgenic Tg2576 mice (gift of K. Hsaio) and their wild type litter mates on a B6/SJL background were bred in our animal facilities. The mice were anesthetized with Ketamine/Xylazine and sacrificed. The cerebral penetrating arterioles were excised from the distribution of the middle cerebral artery. Arterioles with a length of 500 to 1000 μm were transferred to an organ bath (2.5 ml volume) mounted on the stage of an inverted video microscope (Zeiss 100TV or Zeiss 200), and cannulated with glass micropipettes. No intraluminal flow was applied and the transmural pressure was set at 50 mm Hg (mice) or 60 mmHg (rats) and continuously monitored. We observed the internal diameter of the vessels using a computerized diameter tracking system (Diamtrak, T.O. Neild, Flinders University, Adelaide, Australia) with a spatial resolution of 0.5 μm/pixel and a data acquisition rate of 10 Hz. Rat arterioles averaged a maximum passive diameter of 64.9 ± 13.6 μm. Mouse arterioles averaged maximum passive diameters of 51.8 ± 7.7 μm for WT littermates and 52.7 ± 7.0 μm for APPsw mice.

The arterioles were superfused continuously with a physiological saline solution (37.5°C; pH 7.3) of the following composition (in mmol/L): 144 NaCl, 3 KCl, 2.5 CaCl2, 1.4 MgSO4, 2.0 pyruvate, 5.0 glucose, 0.02 ethylenediaminetetraacetic acid (EDTA), and 2.0 3-(N-morpholino) propanesulfonic acid (MOPS), 1.21 NaH2PO4. After equilibration, the vessels developed spontaneous tone and we confirmed their viability by changing the extraluminal pH from 7.3 to 6.8 and from 7.3 to 7.65. Vessels with poor tone (less than 20% decrease from the maximum diameter) or poor response to pH (less than 15% change in diameter after pH change) were excluded.

Pharmacological studies

Stock solutions of commercially available amyloid β peptides were prepared in distilled water (one mmol/L), kept frozen until use and diluted in physiological buffer just prior to use. Using Western blot, we confirmed that the preparations contained predominantly monomeric peptides (data not shown). Similarly, adenosine tri-phosphate (ATP) stock was prepared in distilled water (10 mmol/L) and kept frozen until use. Mn(III) tetrakis (4-benzoic acid) porphyrin (MnTBAP), catalase and superoxide dismutase (SOD) were used to scavenge oxygen radicals. For dose response or agonist studies, the vessel where pretreated with respective Aβ concentrations for 20 minutes. Agonists such as ATP where applied in the presence of amyloid β. Purinergic P2X1 receptors were inhibited with pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS, 3 μmol/L) [24].

Amyloid peptides were purchased from American Peptide Co. (Sunnyvale, CA); all other chemicals were obtained from Sigma (St. Louis, MO).

CAA coverage on TG2576 mouse cerebral arterioles was visualized according to our previously published method using Thioflavin-S (0.005% in MOPS buffer) to visualize CAA. Qualitatively, the vessels in this study were affected to the same extent by CAA as was shown in our previous publication [8].

Cell Culture

Rat cerebral microvascular endothelial and smooth muscle cell lines (obtained from Dr. Diglio, Wayne State University, Michigan) [25, 26] were cultured in antibiotic free DMEM with 10% FCS at 37°C at 95% CO2 and 5% air. Though cell cultures may have undergone changes compared to native cells, in preliminary experiments we confirmed that the endothelial cells tested positive for endothelial nitric oxide and the smooth muscle cells for f-actin thus retaining their respective main phenotype. Cell suspensions were plated into 96 well plates and grown to near confluency. On the day of experiment, the cells were washed with warmed (37°C) Medium Leibovitz, loaded with the oxygen radical sensitive dye MitoTracker Red CM-H2XRos (Invtirogen, diluted in Medium Leibovitz at 5 μmol/L) and incubated for 15 to 20 minutes. After incubation, the cells were washed with warmed Medium Leibovitz, freshly dissolved Aβ was added (one and two μmol/L) immediately before the measurement and the change in fluorescence measured for 30 minutes at 37°C with a plate reader (Synergy HTTR with KC4 software, Biotek Instruments, Ex = 475 ± 15 nm, Em = 645 ± 40 nm). Oxidation of MitoTracker Red CM-H2XRos by ROS increases the dye's fluorescence 100-fold rendering it very sensitive as a detector of ROS. In preliminary experiments we also tested 100 nM Aβ which had insignificant effect and was not used further.


All data are presented as mean ± SEM, with n representing the number of observations. Statistics were conducted on absolute vessel diameters. Differences were considered significant at p < 0.05 and determined by repeated-measures analysis of variance RANOVA with Student-Newman-Keuls test as post test or paired Student's t-test where appropriate. For the Aβ dose response studies, the data are presented as relative diameter change (% relative vessel Diameter = DATP/DTone *100) where DTone is the baseline diameter of the vessel before the stimulation with ATP, and DATP is the diameter of the vessel after the stimulation. For experiments with Aβ pre-incubation and mouse vessels the data are presented as percent maximal diameter and was calculated by the following formula: % maximum dilation = [(DATP - Dtone)/(Dmax - Dtone)]* 100, where Dmax is the maximum diameter of the vessel at 60 mm Hg before the development of spontaneous tone [24, 27]. This method corrects for changes in arteriolar to due to Aβ incubation. Changes in fluorescence intensity are presented as percent change from time zero time over 30 minutes of observation time.


Extraluminal application of soluble Aβ1-40, Aβ1-42 the reverse peptide Aβ40-1on arteriolar tone and myogenic response

Rat penetrating cerebral arterioles exposed to Aβ1-40 had a maximum diameter of 63.2 ± 4.1 um and developed a spontaneous tone diameter of 46.9 ± 3.3 um (n = 8). Freshly dissolved Aβ1-40 resulted in constriction of penetrating arterioles in a dose dependent manner which was significant at a concentration of 0.1 and 1 μmol/L resulting in a reduction of the tone diameter by 26.3 ± 2.9% (Figure 1A).
Figure 1

Effect of freshly dissolved Aβ on rat penetrating arteriolar vessel tone, myogenic response and effect on ATP induced vasomotor responses. Cerebral arterioles ex vivo were treated with increasing concentrations of Aβ1-40, Aβ1-42 or reverse peptide Aβ40-1 and the effect on arteriolar tone measured. (A)Aβ1-42 constricts the arterioles similarly to Aβ1-40 at 0.1 μmol/L while at 1 μmol/L Aβ1-40 has a greater effect. * and ! denote p < 0.05 from control (ANOVA). The reverse peptide Aβ1-40 had no effect. (B) Arterioles pretreated with Aβ1-40 (0.1 μmol/L) lose myogenic response at 120 mmHg intraluminal pressure. Returning to 60 mmHg baseline pressure reestablished control tone diameter. * denotes p < 0.05 from control (n = 3 vessels). Cerebral arterioles were treated with Aβ and vasomotor responses to extraluminal ATP were observed. (C) Aβ1-40 and (D) Aβ1-42 reduce vasodilation to ATP at 1 and 100 μmol/L concentrations. In addition Aβ1-42 also enhances constriction at 100 μmol/L ATP. * denotes p < 0.05 between before and after amyloid peptide (ANOVA).

Vessel exposed to Aβ1-42 had a maximum passive diameter of 78.0 ± 8.7 μm and developed a spontaneous tone diameter of 56.8 ± 7.1 μm. Freshly dissolved Aβ1-42 constricted the penetrating arterioles significantly at 0.1 and 1μmol/L, an effect similar to that seen with Aβ1-40 (Figure 1A). However, at one μmol/L Aβ1-40, there was a 13% stronger constriction compared to Aβ1-42 (p < 0.05).

Vessels treated with the reverse peptide Aβ40-1 had a maximum diameter of 64.8 ± 7.2 μm and a spontaneous tone diameter of 46.6 ± 5.6 μm (n = 4). The reverse peptide had no effect on the tone diameter (Figure 1A).

Myogenic response describes the ability of arterial blood vessels to maintain a constant vessel tone over a range of intraluminal pressures, a mechanism important for cerebral autoregulation. The arterioles used had a maximum diameter of 76.5 ± 13.5 μm and a tone diameter of 60.7 ± 10.7 μm before and of 51.5 ± 9.3 μm after Aβ1-40 (0.1 μmol/L). Under control conditions, vessels maintained their diameter as intraluminal pressure increased from 60 mmHg to 90 mmHg and 120 mmHg. After incubation with freshly dissolved Aβ1-40 (0.1 μmol/L) the vessels' ability to maintain myogenic responses was eliminated at 120 mmHg intraluminal pressure but not at 90 mmHg. The vessels returned to base line diameters at 60 mmHg indicating that the pressure increase did not permanently damage the vessels (Figure 1B).

Arteriolar response to adenosine tri-phosphate (ATP) and soluble Aβ1-40 and Aβ1-42

Extraluminal ATP causes a biphasic vessel response with a transient constriction caused by smooth muscle P2X1-receptors and a subsequent endothelium dependent dilation via P2Y-receptors [24] thus allowing studies of both smooth muscle- and endothelium-dependent responses. We confirmed that ATP causes a transient constriction via P2X1 stimulation in mouse cerebral arterioles. PPADS (3 μmol/L) significantly inhibited constriction to ATP (100 μmol/L) from -16.6 ± 1.2% to -1.3 ± 0.7% (n = 3) while dilation to ATP was unchanged (data not shown). Arterioles treated with Aβ1-40 had a passive maximum diameter of 58.6 ± 3.7 μm and spontaneously constricted to 41.2 ± 3.6 μm (n = 5). Vessels treated with Aβ1-42 had a maximum diameter of 69.5 ± 5.4 and a tone diameter of 48.2 ± 4.1 μm. Both freshly dissolved Aβ1-40 and Aβ1-42 (one μmol/L) significantly decreased dilation to ATP indicating that endothelium dependent dilation was reduced (Figure 1C and 1D). While the constrictory response to ATP was unchanged in the presence of Aβ1-40, we observed an enhanced smooth muscle-dependent constriction with Aβ1-42 with 100 μmol/L concentrations of ATP (Figure 1D). Repeated application of ATP alone (100 μmol/L) did not change the vessel response (relative first constriction of -66.6 ± 7.1% and dilation of 46.2 ± 5.4% versus repeated constriction of -53.2 ± 6.4% and 39.2 ± 7.2% dilation, n = 4 vessel, repeated measures ANOVA).

Soluble Aβ and ROS

Soluble Aβ may cause ROS production in cerebral vessels. We applied the reactive oxygen scavenger MnTBAP (1 to 100 μmol/L) and found that in the presence of Aβ1-40 (1 μmol/L) MnTBAP partially restored vessel tone and diameter at the highest MnTBAP concentration (Figure 2). MnTBAP itself had no effect on the vessel diameter.
Figure 2

Attenuation of Aβ 1-40 -induced vessel constriction by ROS scavenging. Cerebral arterioles were incubated with 100 nmol/L Aβ1-40 and/or the ROS scavenger MnTBAP. MnTBAP reduced Aβ1-40-induced vessel constriction at 100 μmol/L indicating that the Aβ effect is partially due to reactive oxygen species. * denotes p < 0.05 from Aβ alone (n = 3). MnTBAP itself had no effect on the vessel diameter (n = 5).

Microvascular endothelial and smooth muscle cells, Aβ1-40 and Aβ1-42and ROS

To study a possible contribution of reactive oxygen species in the observed vessel dysfunction, we loaded cultured rat cerebral microvascular endothelial or smooth muscle cells with the ROS sensitive dye MitoTracker Red CM-H2XRos. We found that after 30 minutes of incubation, both freshly dissolved Aβ1-40 and Aβ1-42 significantly and dose dependently increased ROS production in the two cell types with Aβ1-42 having a greater effect in endothelial cells compared Aβ1-40 (Figure 3A and 3B). In smooth muscle cells, Aβ1-42 was more effective at 1 μmol/L than Aβ1-40 in producing ROS (Figure 3C and 3D). Aβ (100 nM) induced production of ROS was inhibited by the ROS scavenger MnTBAP (Figure 4), but not by SOD (60 U/ml, Figure 5) or Catalase (40 U/ml, data not shown). These data correspond with our ex vivo observation that MnTBAP reduces the effect of Aβ indicating that ROS are involved in the observed vascular dysfunction. However, it is possible that cultured cells may not correctly reflect in vivo situations.
Figure 3

Dose dependent increase of oxygen radical production induced by soluble Aβ in cultured rat cerebral microvascular cells. To quantify Aβ-induced ROS production in vascular cells, rat cerebral microvascular endothelial and smooth muscle cells were incubated with soluble Aβ (1 and 2 μmol/L) and ROS production was measure using the ROS sensitive dye MitoTracker Red CM-H2XRos (5 μmol/L). (A) Aβ1-40 and (B) Aβ1-42 increase dose-dependently ROS in endothelial ECs) and (C and D) smooth muscle cells (SMCs). * denotes p < 0.05 from control. In SMCs Aβ1-42 has a stronger effect compared to Aβ1-40as indicated by † = p < 0.05. N ≥ four replicates with four cultures per replicate (n ≥ 16). n.s. denotes not significant.
Figure 4

Scavenging of oxygen radical production in rat cerebral microvascular endothelial and smooth muscle cells. ROS production was measured in rat cerebral microvascular endothelial and smooth muscle cells using the ROS sensitive dye MitoTracker Red CM-H2XRos (5 μmol/L). MnTBAP (100 μmol/L) inhibits the increase in (A) Aβ1-40- and (B) Aβ1-42-induced oxygen radical production both in cultured rat cerebral microvascular endothelial cells and in smooth muscle cells (C and D). † denotes p > 0.05 from Control; * denotes p > 0.05 MnTBAP versus respective Control (ANOVA). N > three replicates with three cultures per replicate (n ≥ 9).
Figure 5

Effect of superoxide dismutase (SOD) on Aβ-induced ROS increase. ROS production was measured in rat cerebral microvascular endothelial and smooth muscle cells using the ROS sensitive dye MitoTracker Red CM-H2XRos (5 μmol/L). SOD was unable to attenuate Aβ1-40-induced reactive oxygen radical increase in either (A) endothelial (ECs) or (B) smooth muscle cells (SMCs). * denotes p > 0.05 from Control. N > three replicates with three cultures per replicate (n ≥ 9).

Arteriolar vasomotor responses and chronic exposure to soluble Aβ

We compared vasomotor responses to ATP ex vivo in penetrating arterioles from Tg2576 mice of 3, 6 and 12 months of age compared to age matched wild type littermates. Tg2576 mice develop Aβ deposition in the brain and arterioles beginning at 9 months of age [28, 29]. Wild type vessels had maximum diameter of 53.5 ± 6.5 μm, 61.8 ± 3.6 μm and 54.8 ± 5.3 μm at 3, 6 and 12 months of age, respectively. The tone development was 16.5 ± 6.5 ± 1.2% (n = 24), 13.3 ± 2.9% (n = 4) and 9.8 ± 6.2% (n = 4). Vessels from Tg2576 mice had a maximum diameter of 54.0 ± 3.5 μm, 55.8 ± 2.8 μm and 54.6 ± 2.6 μm at 3, 6 and 12 months of age, respectively. The tone development was 6.8 ± 0.5% (n = 3), 26.5 ± 8.0% (n = 4) and 1.8 ± 1.4% (n = 6). We found no difference in the responses to ATP 3 at months (Figure 6A). At six months of age dilatory response to ATP was reduced in the Tg2576 vessels compared to wild type vessels. At 12 months of age, both dilatory and constrictory vasomotor responses to ATP were virtually absent in Tg2576 vessels while the wild type vessels still showed a constriction to ATP followed by a small dilation (Figure 6A). We measured amyloid coverage in three vessels which was 67.9 ± 4.0%. To test if the vessels from the 12 month old Tg2576 mice can respond to other vasoactive stimuli, we applied alkaline buffer of pH 7.65 and observed a constriction of 10.9 ± 5.2%, indicating that the arterioles still have some capacity to respond other stimuli.
Figure 6

Vasomotor responses to ATP in penetrating arterioles of 3, 6 and 12 months old Tg2576 and WT litter mates and attenuation of Aβ 1-40 induced vessel constriction by 4G8 antibody. Vasomotor responses to extraluminal ATP were measured in cerebral arterioles of control littermate and TG2576 mice ex vivo. (A) At three months of age, the vessels show strong responsiveness to extraluminal ATP both in Tg2576 and WT-LM. At six months, dilation to ATP is reduced in Tg2576 mice. At 12 months, vasomotor responses in Tg2576 vessels are greatly reduced and the vessels show smooth muscle cells enveloped by amyloid. Insert: Thioflavin-S staining of an arteriole (44 μm diameter) from a Tg2576 mouse used in the experiments. * denotes p > 0.05 from WT at same age. (B) Incubation with Aβ1-40 caused a significant arteriolar constriction which lasted at least for 30 minutes after washout. The soluble Aβ-specific antibody 4G8 restored control vessel tone while the control IgG did not. * = p < 0.05 from tone diameter for both control IgG and 4G8 treated vessels; t = p < 0.05 from Aβ1-40-induced constriction; n.s = not significant from Aβ1-40-induced constriction.

Extraluminal application of anti-Aβ antibody 4G8

Passive immunization with certain anti Aβ antibodies has shown that such treatment can rapidly improve cognitive function in animal models of AD [30]. We tested the hypothesis that antibody treatment can interfere with the effect of soluble Aβ on cerebral arterioles. Arterioles were first treated with freshly dissolved Aβ1-40, the Aβ washed out, treated with the anti-Aβ antibody 4G8 antibody (1:200 dilution) and finally the 4G8 washed out. Each treatment applied for 30 minutes and the diameter measured at the end of each treatment. Freshly dissolved Aβ1-40 significantly constricted the arterioles and this constriction remained even after 30 minutes of washout. Incubation with 4G8 antibody with the vessels, 30 minutes after Aβ1-40 washout, restored vessel tone (Figure 6B). For control experiments we replaced 4G8 antibody with non-specific IgG antibody. In this control experiment non-specific IgG did not restore vessel tone showing that Aβ1-40 has a prolonged vasoconstrictive effect even after prolonged washout (Figure 6B). This indicates that Aβ1-40 may interact with the vessel even after washout and that antibody to soluble Aβ may interfere with this interaction.


Our study has several notable findings, including the following: 1) freshly dissolved Aβ1-40 and Aβ1-42, but not the reverse peptide Aβ40-1, acutely increase vessel tone in rat cerebral penetrating arterioles, with Aβ1-42 being equally potent to Aβ1-40 except at the highest concentration; 2) Aβ1-40 and Aβ1-42 both decrease endothelium-dependent dilation to ATP, with Aβ1-42 also enhancing smooth muscle dependent constriction; 3) Aβ1-40 decreases arteriolar myogenic response; 4) MnTBAP attenuates Aβ1-40-induced increase in vessel tone increase suggesting that reactive oxygen species have a contributing role in Aβ-induced enhancement in vessel tone; 5) Aβ1-40 and Aβ1-42 acutely increased ROS production in cultured rat cerebral microvascular endothelial and smooth muscle cells in a dose dependent fashion - a response that was inhibited by the cell permeable ROS scavenger MnTBAP but not SOD or catalase; 6) Incubation of penetrating arterioles with Aβ1-40 for 30 minutes resulted in prolonged increased tone which was not restored by Aβ washout but was restored by the anti-Aβ antibody, 4G8; and 7) exposure to soluble as well as deposited Aβ decreased vascular reactivity over time in arterioles from Tg2576 mice, an animal model of AD. These results confirm many previous reports but also extend our understanding of the vascular effects of soluble Aβ, especially in regards to the pathological effects of Aβ1-42 on vessels and vascular cells. These results indicate a direct effect of the studied Aβ species on cerebral penetrating arterioles with potentially important differences in their activity such as enhanced arteriolar vasoconstriction to ATP or increased ROS production by Aβ1-42 but increased vessel constriction by Aβ1-40.

The penetrating cerebral arteriole is an important regulator of CBF representing about 25% of the total cerebral arterial regulatory capacity. Further, it is the part of the cerebral circulation most profoundly involved in the trafficking of Aβ from the brain [21] and continuously exposed to Aβ. Though the concentration of Aβ in the CSF is in the nanomolar range [31] the concentration in the periarteriolar space is not known and could be higher especially when transport across the arteriole is compromised and Aβ accumulates. Such accumulation would eventually lead to CAA [32]. So far no study has directly addresses the effect of soluble Aβ in this essential microvessel.

Soluble Aβ

In CAA, amyloid deposition consists predominantly of Aβ1-40 rather than Aβ1-42 species [33]; however, in most cases of CAA, Aβ1-42 may initially be necessary to induce amyloid deposition [34]. Thus initial studies related to the effect of freshly dissolved Aβ on cerebral vessels that concentrated on Aβ1-40 [15]. Niwa et al. directly compared the effects of soluble Aβ1-40 versus Aβ1-42 in mouse cerebral circulation and found that Aβ1-40 but not Aβ1-42 recapitulated the observed vascular dysfunction in a mouse model of AD with a high Aβ1-40 to Aβ1-42 ratio [5, 6, 8]. Similarly, in rat aorta, Aβ1-42 was less effective than Aβ1-40 [35]. Our data indicate that at concentrations up to 100 nmol/L both Aβ species have a similar effect on rat cerebral arteriolar tone (though at concentrations higher than 100 nmol/L Aβ1-40 produced greater arteriolar tone). Previous studies found that Aβ1-40 reduced endothelium dilation to variety of agonists as well as physiological whisker stimulation [15, 19] while Aβ1-42 and the reverse peptide Aβ40-1 did not [5, 6, 12]. Adenosine tri-phosphate (ATP) is an important cerebral vasoactive agonist which can be released from numerous sources including cerebral purinergic nerves, astrocytes and red blood cells [36]. Extraluminally applied ATP causes a biphasic diameter response in cerebral arterioles with an initial transient constriction due to smooth muscle cells purinergic P2X1-receptors [24, 36] which quickly desensitize [37] followed by an endothelium-dependent dilation via P2Y-receptors [24, 36]. The effect of Aβ species on ATP-induced vasomotor responses has not been reported previously. We found that similar to other endothelium-dependent agonists, Aβ1-40 and Aβ1-42 reduce dilation to ATP. Agonist-induced constriction with endothelin or serotonin is increased after Aβ1-40 [15]; however, this enhanced constriction was attributed to decreased endothelial function rather than an effect on smooth muscle cells [5, 6, 15]. In mice intraluminal Aβ1-40 caused an endothelin-dependent decrease in CBF which was attenuated by inhibiting the receptor for advanced glycation end products (RAGE) [38]. In our study we found that Aβ1-42 but not Aβ1-40 enhances constriction to ATP. This constrictive response to ATP is mediated via smooth muscle cells (endothelial denudation does not affect ATP-induced vasoconstriction [36]) and is likely due to desensitization of the P2X1-receptor responsible for constriction by limiting the time of its activity [36]. The enhanced constriction observed with Aβ1-42 likely means that it has a direct effect on smooth muscle cell function either by Aβ1-42 prolonging the open probability of the P2X1-receptor or by enhancing the sensitivity of the smooth muscle contractile apparatus. Freshly dissolved Aβ1-40 also decreases arteriolar myogenic response. That increased Aβ may decrease myogenic response was shown in a mouse model of AD [6].

Passive immunization with anti-Aβ antibodies is being evaluated as a possible treatment for AD [39]. Dodart et al. showed that passive immunization could rapidly (within 24 to 72 hours) improve cognitive function in an animal model of AD [30]. We therefore hypothesized that an antibody against Aβ may rapidly ameliorate Aβ-induced increase in arteriolar tone. We found that a 30 minute incubation with Aβ1-40 resulted in a persistent (> 90 minutes) increase in arteriolar tone despite repeated washouts. This indicates that, once in contact with the vessel, Aβ1-40 retains its vasoactive effect even in the absence of extravascular Aβ for some time. However, after application of the anti-Aβ antibody 4G8, the arteriolar tone was restored while non-specific IgG had no effect. This observation is consistent with the notion that Aβ1-40 resides on the cell surface in such a way that only high affinity binding agents can remove or neutralize. Alternatively the Aβ signaling mechanism may be slow to come on and slow to turn off. Further studies are needed to resolve the mechanism of soluble Aβ-induced arteriolar dysfunction. Taken together we present for the first time evidence that soluble Aβ1-40 as well as Aβ1-42 directly impair cerebral penetrating arteriolar function and that Aβ1-42 may be considered a vasoactive Aβ species in this preparation.


The mechanism behind cerebral vascular dysfunction due to soluble Aβ is not completely understood. There is evidence that ROS are involved [15, 1719]. Since peroxynitrite did not duplicate soluble Aβ-induced vascular dysfunction in rat aorta [17], superoxide anion produced by NADPH oxidase may contribute to the observed vascular dysfunction [17, 18]. Other studies suggest that soluble Aβ causes activation of COX-2 and other inflammatory responses resulting in the observed vascular dysfunction [13, 40]. Soluble Aβ may trigger intracellular calcium mobilization which may activate calcium sensitive PKCs resulting in deactivation of eNOS [16].

We applied the cell permeant oxygen radical scavenger MnTBAP to cerebral arterioles ex vivo and found a partial restoration of arteriolar tone, indicating that oxygen radicals contribute to the increased tone development by Aβ. To further elucidate the acute effect of freshly dissolved Aβ on vascular cells, we measured ROS production in rat cerebro-microvascular endothelial and smooth muscle cells. Our results show, that freshly dissolved Aβ1-40 and Aβ1-42 dose-dependently increase ROS production in both endothelial and smooth muscle cells with Aβ1-42 having a greater ability to induce oxygen radical formation. This indicates that both Aβ species may acutely interfere with either cell type and their function in vascular regulation. Studies show that extraluminal Aβ1-40 damages cerebrovascular endothelium and impairs function within 30 minutes of incubation [15, 40] indicating that Aβ quickly reacts with vascular cells. This suggests that Aβ may reach the abluminal endothelium to exert a direct endothelial effect similar to other small peptides such as bradykinin. While we and others found that Aβ directly affects endothelial cells in culture, experiments with extraluminal Aβ application are not consistent as to whether extraluminal Aβ directly affects the endothelium or if the Aβ effect is limited to the vascular smooth muscle from which a noxious mediator may diffuse to the endothelium. Catalase and superoxide dismutase (SOD) did not affect the Aβ-induced ROS production. MnTBAP is a cell permeable SOD-mimetic, as such MnTBAP scavenges O2- at the source, presumably the mitochondria. SOD is not cell permeant and O2- does not diffuse well out of the cell due to its polarity. As such SOD is expected to have less or no effect of scavenging intracellular ROS. Catalase metabolizes H2O2 to H2O and O2-. H2O2 is cell permeant and could be metabolized by extracellular catalase. However, since catalase did not change the ROS signal, H2O2 may not be involved in the observed ROS production. No study on the acute effect of Aβ-induced ROS on cerebral microvascular endothelial cells in vitro exists though cytotoxicity following a 24 hour exposure of cells incubated with Aβ1-40, was reduced by MnTBAP in RBE4 cells indicating that ROS were produced [17]. A consequence of oxidative stress is increased lipid peroxidation, measured e.g. as thiobarbituric acid reactive substances (TBARS), which was increased in cultured astrocytes after 24 hour incubation with Aβ1-40 [41]. While we were able to detect an increase in ROS with MitoTracker Red CM-H2XRos fluorescence, in preliminary experiments we could not detect an increase in lipid peroxidation with thirty minutes of Aβ incubation. It is likely that this incubation time is not long enough to result in a lipid peroxidation detectable by the TBARS method and more sensitive approaches such a mass spectroscopy have to be used.

Though no observations for acute effects exist, differences in the effect of Aβ species on endothelial cells were found in several studies. Folin et al. found that Aβ1-40 was less toxic to neuro-endothelial cells than Aβ1-42 [42] while the opposite was found for human cerebrovascular endothelial cells [43]. In other vascular endothelial cells it was found that Aβ1-40 reduces production of nitric oxide [16, 20]. The effect of the vasculotropic Dutch (E693Q)/Iowa (D694N) mutant human Aβ1-40D was studied in human cerebro-vascular smooth muscle cells. The study found that Aβ1-40D did not increase ROS production [44]. Other mechanisms such as increased intracellular calcium activity [16] or decreased endothelial nitric oxide availability [20] have been reported which could also contribute to the observed vascular dysfunction.

Chronic exposure to soluble Aβ

To test if chronic exposure to increased Aβ levels affects arteriolar vasomotor function over time, we compared arteriolar diameter responses of vessels from Tg2576 mice, a commonly used AD mouse model having elevated levels of soluble Aβ throughout life and age-dependent development of CAA [28], with age matched littermate controls. We found no difference in vessel responses to ATP at three months of age, but at six months of age, dilation to ATP was reduced in Tg2576 mice. There was also a trend towards increased tone and increased ATP-induced vasoconstriction, but this did not reach statistical significance. In 12 month old Tg2576 mice, the vasomotor response to ATP was essentially absent. Stimulation with alkaline pH still resulted in some constriction indicating that the vessels were responsive to some physiological stimulus. At this age, the vessels evaluated had CAA coverage of approximately 67%. Amyloid can also be sequestered in the basement membrane [45, 46] which may be more likely to occur with basement membrane thickening that occurs with age. This will affect vessel functionality. Further accumulation of soluble Aβ could lead to formation of Aβ oligomers which in some studies are shown to be more effective/toxic than monomeric soluble Aβ [47]. The possible effect of Aβ oligomers on cerebral arterioles will be important to assess in future experiments. The lack of vasodilation in these vessels corresponds well with in vivo observations in pial arterioles where a CAA coverage of 50% or more eliminated dilatory response to hypercapnia [8]. The same study also found that in 12 month old TG2576 vessels, the smooth muscle content was significantly reduced. Thus increased CAA coverage and decreased smooth muscle content could, in part, explain the weak constrictory response observed at this age in our ex vivo studies.

Taken together these findings indicate that on the arteriolar level, chronic exposure to Aβ may lead to alterations in vasomotor function as early as six months of age when no amyloid deposits are present [5, 8]. Though vessel function decreases with age, it deteriorates severely in Tg2576 animals. Relative CBF was found to be decreased in 13 month old Tg2576 mice [7]. CBF responses to a variety of stimuli in Tg2576 mice of 8 months (pre-CAA) was not different from age matched controls though they were depressed in 19 month old animals [9, 10]. While our and the above studies did not observe vascular anomalies in Tg2576 mice younger than 6 months of age, Niwa et al. found decreased CBF responses in young (two to three months) Tg2576 mice [6]. It should be noted, however, that our data at 3 months of age did show a trend for decreased dilation and increased vasoconstriction in Tg2576 mice indicating that increased Aβ may have begun to effect cerebral arteriole function early in life.


Utilizing isolated rat cerebral arterioles ex vivo, we found that both Aβ1-40 and Aβ1-42 cause vessel constriction and reduced dilation to ATP, with Aβ1-42 also enhancing arteriolar constriction response. Together with the observed loss of myogenic response, increased soluble Aβ levels may lead to pronounced vessel dysfunction in vivo. Both Aβ1-40 and Aβ1-42 increased oxygen radical production in cerebro-microvascular endothelial and smooth muscle cells which was inhibited by MnTBAP, indicating that oxygen radicals, in part, contribute to Aβ-induced penetrating arteriole dysfunction. The effects of Aβ-incubation on cerebral arterioles persists after washout but can be alleviated with an anti-Aβ antibody, suggesting that Aβ may exert its effects while bound to the cell surface. Chronic exposure to elevated Aβ results in cerebral microvascular dysfunction before CAA at six months of age which worsened with age resulting in minimal responsiveness at 12 months with CAA present. Overall the results suggest that soluble and fibrillar Aβ is influencing arteriolar function which may have an important effect on brain dysfunction in AD and CAA and may contribute to ischemia.



This work was supported by National Institutes of Health (NIH) grants NS032636 (HHD, GJZ and DMH), AG13956 (DMH), NS053899 (GJZ), NS30555 (HHD) and HL41250 (HHD) and American Health Assistance Foundation (GJZ).

Authors’ Affiliations

Department of Neurological Surgery, Hope Center for Neurological Disorders, and Alzheimer's Disease Research Center, Washington University School of Medicine
Department of Neurological Surgery, Washington University School of Medicine
Departments of Neurological Surgery, Neurology, and Hope Center for Neurological Disorders, Washington University School of Medicine
Department of Neurology, Hope Center for Neurological Disorders, and Alzheimer's Disease Research Center, Washington University School of Medicine


  1. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001, 81: 741-766.PubMedGoogle Scholar
  2. Steiner H, Haass C: Intramembrane proteolysis by presenilins. Nat Rev Mol Cell Biol. 2000, 1: 217-224. 10.1038/35043065.PubMedView ArticleGoogle Scholar
  3. Ruitenberg A, den HT, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, Breteler MM: Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol. 2005, 57: 789-794. 10.1002/ana.20493.PubMedView ArticleGoogle Scholar
  4. Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C: Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci. 1997, 17: 7655-7661.PubMedGoogle Scholar
  5. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C: Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci USA. 2000, 97: 9735-9740. 10.1073/pnas.97.17.9735.PubMedPubMed CentralView ArticleGoogle Scholar
  6. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C: Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol. 2002, 283: H315-H323.PubMedView ArticleGoogle Scholar
  7. Paris D, Quadros A, Humphrey J, Patel N, Crescentini R, Crawford F, Mullan M: Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res. 2004, 999: 53-61. 10.1016/j.brainres.2003.11.061.PubMedView ArticleGoogle Scholar
  8. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, Cirrito JR, Milner E, Holtzman DM, Zipfel GJ: Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci. 2008, 28: 13542-13550. 10.1523/JNEUROSCI.4686-08.2008.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Shin HK, Jones PB, Garcia-Alloza M, Borrelli L, Greenberg SM, Bacskai BJ, Frosch MP, Hyman BT, Moskowitz MA, Ayata C: Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain. 2007, 130: 2310-2319. 10.1093/brain/awm156.PubMedView ArticleGoogle Scholar
  10. Christie R, Yamada M, Moskowitz M, Hyman B: Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol. 2001, 158: 1065-1071.PubMedPubMed CentralView ArticleGoogle Scholar
  11. Suo Z, Humphrey J, Kundtz A, Sethi F, Placzek A, Crawford F, Mullan M: Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett. 1998, 257: 77-80. 10.1016/S0304-3940(98)00814-3.PubMedView ArticleGoogle Scholar
  12. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C: Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol. 2001, 281: H2417-H2424.PubMedGoogle Scholar
  13. Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, Mullan M: Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res. 2003, 25: 642-651. 10.1179/016164103101201940.PubMedView ArticleGoogle Scholar
  14. Thomas T, McLendon C, Sutton ET, Thomas G: Cerebrovascular endothelial dysfunction mediated by beta-amyloid. Neuroreport. 1997, 8: 1387-1391. 10.1097/00001756-199704140-00014.PubMedView ArticleGoogle Scholar
  15. Price JM, Sutton ET, Hellermann A, Thomas T: beta-Amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res. 1997, 19: 534-538.PubMedGoogle Scholar
  16. Gentile MT, Vecchione C, Maffei A, Aretini A, Marino G, Poulet R, Capobianco L, Selvetella G, Lembo G: Mechanisms of soluble beta-amyloid impairment of endothelial function. J Biol Chem. 2004, 279: 48135-48142. 10.1074/jbc.M407358200.PubMedView ArticleGoogle Scholar
  17. Paris D, Parker TA, Town T, Suo Z, Fang C, Humphrey J, Crawford F, Mullan M: Role of peroxynitrite in the vasoactive and cytotoxic effects of Alzheimer's beta-amyloid1-40 peptide. Exp Neurol. 1998, 152: 116-122. 10.1006/exnr.1998.6828.PubMedView ArticleGoogle Scholar
  18. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C: NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci. 2005, 25: 1769-1777. 10.1523/JNEUROSCI.5207-04.2005.PubMedView ArticleGoogle Scholar
  19. Niwa K, Carlson GA, Iadecola C: Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab. 2000, 20: 1659-1668. 10.1097/00004647-200012000-00005.PubMedView ArticleGoogle Scholar
  20. Price JM, Chi X, Hellermann G, Sutton ET: Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol Res. 2001, 23: 506-512. 10.1179/016164101101198758.PubMedView ArticleGoogle Scholar
  21. Deane R, Wu Z, Zlokovic BV: RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004, 35: 2628-2631. 10.1161/01.STR.0000143452.85382.d1.PubMedView ArticleGoogle Scholar
  22. Dacey RG, Duling BR: A study of rat intracerebral arterioles: methods, morphology, and reactivity. Am J Physiol. 1982, 243: H598-H606.PubMedGoogle Scholar
  23. You JP, Johnson TD, Marrelli SP, Bryan RM: Functional heterogeneity of endothelial P2 purinoceptors in the cerebrovascular tree of the rat. Am J Physiol Heart Circ Physiol. 1999, 277: H893-H900.Google Scholar
  24. Dietrich HH, Horiuchi T, Xiang C, Hongo K, Falck JR, Dacey RG: Mechanism of ATP-induced local and conducted vasomotor responses in isolated rat cerebral penetrating arterioles. J Vasc Res. 2009, 46: 253-264. 10.1159/000167273.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Diglio CA, Grammas P, Giacomelli F, Wiener J: Rat cerebral microvascular smooth muscle cells in culture. J Cell Physiol. 1986, 129: 131-141. 10.1002/jcp.1041290202.PubMedView ArticleGoogle Scholar
  26. Diglio CA, Wolfe DE, Meyers P: Transformation of rat cerebral endothelial cells by rous sarcoma virus. J Cell Biol. 1983, 97: 15-21. 10.1083/jcb.97.1.15.PubMedView ArticleGoogle Scholar
  27. You JP, Johnson TD, Marrelli SP, Mombouli JV, Bryan RM: P2u receptor-mediated release of endothelium-derived relaxing factor nitric oxide and endothelium-derived hyperpolarizing factor from cerebrovascular endothelium in rats. Stroke. 1999, 30: 1125-1132.PubMedView ArticleGoogle Scholar
  28. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996, 274: 99-102. 10.1126/science.274.5284.99.PubMedView ArticleGoogle Scholar
  29. Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM: Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci. 2003, 23: 7889-7896.PubMedGoogle Scholar
  30. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, et al: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002, 5: 452-457.PubMedGoogle Scholar
  31. Oh ES, Troncoso JC, Fangmark Tucker SM: Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med. 2008, 10: 195-207. 10.1007/s12017-008-8035-0.PubMedPubMed CentralView ArticleGoogle Scholar
  32. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Nostrand W, et al: SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol. 2008Google Scholar
  33. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Younkin LH, Suzuki N, Younkin SG: Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem. 1995, 270: 7013-7016. 10.1074/jbc.270.13.7013.PubMedView ArticleGoogle Scholar
  34. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, et al: Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005, 47: 191-199. 10.1016/j.neuron.2005.06.030.PubMedPubMed CentralView ArticleGoogle Scholar
  35. Suo Z, Fang C, Crawford F, Mullan M: Superoxide free radical and intracellular calcium mediate A beta(1-42) induced endothelial toxicity. Brain Res. 1997, 762: 144-152. 10.1016/S0006-8993(97)00383-1.PubMedView ArticleGoogle Scholar
  36. Horiuchi T, Dietrich HH, Tsugane S, Dacey RG: Analysis of purine- and pyrimidine-induced vascular responses in the isolated rat cerebral arteriole. American Journal of Physiology - Heart & Circulatory Physiology. 2001, 280: H767-H776.Google Scholar
  37. Gever JR, Cockayne DA, Dillon MP, Burnstock G, Ford AP: Pharmacology of P2X channels. Pflugers Arch. 2006, 452: 513-537. 10.1007/s00424-006-0070-9.PubMedView ArticleGoogle Scholar
  38. Deane R, Du YS, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, et al: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003, 9: 907-913. 10.1038/nm890.PubMedView ArticleGoogle Scholar
  39. Brody DL, Holtzman DM: Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008, 31: 175-193. 10.1146/annurev.neuro.31.060407.125529.PubMedPubMed CentralView ArticleGoogle Scholar
  40. Rhodin J, Thomas T, Bryant M, Sutton ET: Animal model of Alzheimer-like vascular pathology and inflammatory reaction. Ann N Y Acad Sci. 2000, 903: 345-352. 10.1111/j.1749-6632.2000.tb06385.x.PubMedView ArticleGoogle Scholar
  41. Matos M, Augusto E, Oliveira CR, Agostinho P: Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience. 2008, 156: 898-910. 10.1016/j.neuroscience.2008.08.022.PubMedView ArticleGoogle Scholar
  42. Folin M, Baiguera S, Tommasini M, Guidolin D, Conconi MT, De CE, Nussdorfer GG, Parnigotto PP: Effects of beta-amyloid on rat neuromicrovascular endothelial cells cultured in vitro. Int J Mol Med. 2005, 15: 929-935.PubMedGoogle Scholar
  43. Eisenhauer PB, Johnson RJ, Wells JM, Davies TA, Fine RE: Toxicity of various amyloid beta peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of dutch-type mutant. J Neurosci Res. 2000, 60: 804-810. 10.1002/1097-4547(20000615)60:6<804::AID-JNR13>3.0.CO;2-1.PubMedView ArticleGoogle Scholar
  44. Jung SS, Van Nostrand WE: Abeta does not induce oxidative stress in human cerebrovascular smooth muscle cells. Neuroreport. 2002, 13: 1309-1312. 10.1097/00001756-200207190-00019.PubMedView ArticleGoogle Scholar
  45. Maat-Schieman M, Roos R, van Duinen S: Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology. 2005, 25: 288-297. 10.1111/j.1440-1789.2005.00631.x.PubMedView ArticleGoogle Scholar
  46. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, et al: Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci. 2004, 7: 954-960. 10.1038/nn1302.PubMedView ArticleGoogle Scholar
  47. Glabe CG: Structural classification of toxic amyloid oligomers. J Biol Chem. 2008, 283: 29639-29643. 10.1074/jbc.R800016200.PubMedPubMed CentralView ArticleGoogle Scholar


© Dietrich et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.